BiotechTube

dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duct Cell Adenocarcinoma of the Pancreas

Conditions

Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Trial Timeline

Mar 1, 2015 → —

NCT ID
NCT02048943

About dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation

dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation is a phase 1 stage product being developed by Novartis for Duct Cell Adenocarcinoma of the Pancreas. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02048943. Target conditions include Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer.

What happened to similar drugs?

7 of 20 similar drugs in Duct Cell Adenocarcinoma of the Pancreas were approved

Approved (7) Terminated (7) Active (9)
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄Napabucasin + Nab-paclitaxel + GemcitabineSumitomo PharmaPhase 3
✅Recombinant FSH (follitropin alpha)MerckApproved
✅Lutropin alfa + Follitropin alfaMerckApproved
🔄Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG)MerckPhase 3
❌Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSHMerckPhase 3
✅OxcarbazepineNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02048943Phase 1Withdrawn

Competing Products

20 competing products in Duct Cell Adenocarcinoma of the Pancreas

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + CapecitabineAstellas PharmaPhase 1
36
LY3962673 + Cetuximab + Gemcitabine + nab-paclitaxel + Oxaliplatin + leucovorin + Irinotecan + 5-fluorouracilEli LillyPhase 1
36
[Ga-68]-PNT6555 + [Lu-177]-PNT6555Eli LillyPhase 1
21
LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + PembrolizumabEli LillyPhase 1
33
Abemaciclib + LY3023414 + Gemcitabine + CapecitabineEli LillyPhase 2
35
Napabucasin + Nab-paclitaxel + GemcitabineSumitomo PharmaPhase 3
40
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
[14C]SHR7280Jiangsu Hengrui MedicinePhase 1
29
Rifampicin treatmentAstraZenecaPre-clinical
26
MEDI4736 in combination with nab-paclitaxel and gemcitabine + MEDI4736 in combination with AZD5069AstraZenecaPhase 1/2
32
Symbicort pMDI with spacer device + Symbicort pMDI without spacer deviceAstraZenecaPhase 1
29
MEDI4736 monotherapy + tremelimumab+MEDI4736AstraZenecaPhase 2
35
Durvalumab + OleclumabAstraZenecaPhase 2
27
Durvalumab + TremelimumabAstraZenecaPhase 2
39